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a  b  s  t  r  a  c  t
The  gill is the  principle  site  of xenobiotic  transfer  to  and  from  the  aqueous  environment.  To replace,
reﬁne  or  reduce  (3Rs)  the  large numbers  of ﬁsh  used  in  in  vivo  uptake  studies  an  effective  in  vitro  screen
is  required  that  mimics  the  function  of  the  teleost  gill.  This  study  uses  a rainbow  trout (Oncorhynchus
mykiss)  primary  gill cell  culture  system  grown  on permeable  inserts,  which  tolerates  apical  freshwa-
ter  thus  mimicking  the intact  organ,  to assess  the  uptake  and  efﬂux  of pharmaceuticals  across  the  gill.
Bidirectional  transport  studies  in  media  of seven  pharmaceuticals  (propranolol,  metoprolol,  atenolol,
formoterol,  terbutaline,  ranitidine  and  imipramine)  showed  they  were  transported  transcellularly  across
the epithelium.  However,  studies  conducted  in water  showed  enhanced  uptake  of propranolol,  ranitidine
and  imipramine.  Concentration-equilibrated  conditions  without  a  concentration  gradient  suggested  that
a proportion  of  the  uptake  of propranolol  and  imipramine  is  via  a carrier-mediated  process.  Further  study
using propranolol  showed  that its transport  is pH-dependent  and  at very  low  environmentally  relevant
concentrations  (ng  L−1),  transport  deviated  from  linearity.  At  higher  concentrations,  passive  uptake  dom-
inated.  Known  inhibitors  of drug  transport  proteins;  cimetidine,  MK571,  cyclosporine  A  and  quinidine
inhibited  propranolol  uptake,  whilst  amantadine  and  verapamil  were  without  effect.  Together  this  sug-
gests  the involvement  of  speciﬁc  members  of  SLC  and  ABC  drug  transporter  families  in  pharmaceutical
transport.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
There are currently over 140,000 compounds that are being
reassessed for their bioconcentrative properties as a part of the
EU Registration, Evaluation, Authorization & Restriction of Chem-
icals (REACH) initiative (REACH, 2009). Conventionally, the main
determinant used for assessing bioconcentration of a compound
is the octanol–water partitioning coefﬁcient (Kow), a measure of
Abbreviations: 3Rs, reduce, reﬁne, replace; A, apical; ABC, ATP-binding cas-
sette; B, basal; BCF, bioconcentration factor; BTA, bi-directional transport assay;
CETA, concentration equilibrated transport assay; Ci, Curie; Dpm, disintegrations
per minute; Kow, octanol–water partitioning coefﬁcient; MRP, multidrug resis-
tance protein; OCT, organic cation transporter; OECD, Organisation for Economic
Co-operation and Development; Papp, apparent permeability coefﬁcient; pKa, dis-
sociation constant; QSARs, quantitative structure–activity relationships; REACH,
Registration, Evaluation, Authorization & Restriction of Chemicals; SLC, solute car-
rier; TER, transepithelial resistance; TEP, transepithelial potential; TR, transport
ratio.
∗ Corresponding author. Tel.: +44 2078484091; fax: +44 2078484500.
E-mail address: Nic.Bury@kcl.ac.uk (N.R. Bury).
hydrophobicity that drives sorption and accumulation, and a main
input parameter in quantitative structure–activity relationships
(QSARs) (Hansch, 1969). However, this may  not be fully applica-
ble to pharmaceuticals, many of which are polar and ionizable
(Hermens et al., 2013). In this case, the pH-corrected octanol–water
partitioning coefﬁcient, Dow, may  be used, but this fails to take into
account other major interactions such as hydrogen bonding and van
der Waals forces, as well as uptake via carrier-mediated processes
(Dobson and Kell, 2008; Sugano et al., 2010).
In vivo ecotoxicology testing produces bioconcentration factor
(BCF) values that indicate the potential of a compound to biocon-
centrate within an organism (OECD305, 2012). Fish are exposed to
highly lipophilic compounds via the diet, whilst to others via the
water; the principle being to use the uptake and depuration rates
to calculate the propensity of a compound to bioconcentrate. Typ-
ically, each test can use up to 108 ﬁsh per compound and many
thousands of ﬁsh are used for this test every year (Scholz et al.,
2013). There is currently a desire to develop alternative methods to
replace these standardized whole ﬁsh studies to recognize and clas-
sify environmental hazards (Creton et al., 2013; Wolf et al., 2007).
This requires the identiﬁcation and validation of appropriate in vitro
http://dx.doi.org/10.1016/j.aquatox.2014.12.007
0166-445X/© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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systems that could replace such studies (Baron et al., 2012; Uchea
et al., 2013). To ﬁnd alternatives to the OECD305 water exposure it
is necessary to identify a suitable ﬁsh gill model that mimics the
intact organ because the gill, being constantly and continuously
exposed to substances in water, is the principle site of xenobiotic
uptake (Bury et al., 2014).
Fletcher et al. (2000) developed a double-seeding technique that
enables primary gill cells to be cultured on permeable membrane
inserts in a two-compartment model. This cultured epithelium
comprises the different cell types (mitochondrial rich cells, respi-
ratory cells and mucus cells) found in the gill and produces
high transepithelial resistance (reviewed by Bury et al., 2014).
Importantly, the system is able to tolerate apical freshwater and
produces a negative transepithelial potential, further simulating
the in vivo scenario. This is crucial when investigating the transport
of ionizable compounds such as pharmaceuticals that may  behave
differently in culture medium and water. Furthermore, the gill cells
from two ﬁsh can be used to create up to 72 individual gill epithe-
lial inserts for assaying, thus potentially reducing numbers of ﬁsh
in in vivo testing.
The present study thus aims to use the in vitro gill to investi-
gate the uptake and efﬂux of seven pharmaceuticals representing
a range of classes. We  hypothesize that both passive transcellu-
lar and carrier-mediated transport of xenobiotics across the gill
are likely principle drivers in determining the rate of uptake of
waterborne compounds (Mckim and Erickson, 1991). Passive tran-
scellular transport depends on the pH of the solution, acid–base
constants (pKa) and the lipophilicity of the compound, whereas
facilitated transport may  be via members of the solute carrier (SLC)
and ATP-binding casette (ABC) transporter families (Dobson and
Kell, 2008). Therefore, to investigate carrier-mediated transport
for some of these pharmaceuticals, concentration-equilibrated,
pH-dependent, and concentration-dependent assays, as well as
membrane channel inhibitor studies were conducted. In the con-
text of this work, paracellular transport refers to the movement
of compounds over membranes between cells and passive trans-
port refers to concentration-dependent transcellular processes,
whereas facilitated transport indicates concentration-independent
carrier-mediated transport via membrane channel proteins. In
addition, the uptake of propranolol across the in vitro gill model was
compared to in silico and in vivo data (Owen et al., 2009), to demon-
strate the use of this model as a predictive tool for pharmaceutical
uptake.
2. Materials and methods
2.1. Animal husbandry
Gill cells for the use in primary cultures were obtained from
juvenile diploid rainbow trout weighing 50–120 g purchased
from a trout farm (Hampshire, UK). Fish were acclimatized in
three 1000 L ﬁberglass aquaria at King’s College, London, and
maintained at 13–14 ◦C in recirculating aerated city of London
tap water ([Na+] = 0.53 mM,  [Ca2+] = 0.92 mM,  [Mg2+] = 0.14 mM,
[K+] = 0.066 mM and [NH4+] = 0.027 mM),  which was passed
through carbon, mechanical and biological ﬁlters. Photoperiod was
maintained at a constant 14 h light/10 h dark cycle and ﬁsh were
fed a daily 1% (w/w) ration of ﬁsh chow.
2.2. Gill cell culture
Sterile techniques were used throughout all cell culture pro-
cedures. Equipment, containers and solutions were autoclaved or
sterile ﬁltered (0.2 m,  Corning). The gill cell isolation procedure
was based on methods previously documented (Fletcher et al.,
2000) and the cell culture double-seeded insert (DSI) technique as
described by Walker et al. (2008) and Wood et al. (2002). Brieﬂy,
primary gill cells are isolated, washed and resuspended in L-15
medium (Invitrogen) supplemented with FBS (5% (v/v)) (Sigma)
and seeded onto a permeable polyethylene terephthalate (PET)
membrane inserts with 0.4 m pores with an area of 0.9 cm2 and
maintained at 18 ◦C. This Transwell system (Corning) has an apical
compartment above and a basal compartment below.
The development of an intact and electrically tight gill epithe-
lium was monitored daily through ‘blank’-corrected measurements
of transepithelial resistance (TER) using a custom-modiﬁed epithe-
lial tissue voltohmeter (EVOMX; World Precision Instruments)
ﬁtted with chopstick electrodes (STX-2). The same device was used
to measure transepithelial potential (TEP) before and after freshwa-
ter application. DSI epithelia that reached a TER of ≥5 k cm2 were
considered developed and electrically ‘tight’ for experimental pro-
cedures. In this instance, DSI preparations were washed twice with
PBS (to remove any media supplemented with FBS) and exposed
to radiolabeled pharmaceuticals apically in either L-15 medium
(without FBS) or freshwater (2.0 mM CaCl2, 0.5 mM MgSO4, 0.8 mM
NaHCO3, 77.1 M KCl at pH 7.7), or basally, always in L-15
medium. L-15 medium has an osmolarity of 300–320 mOsm kg−1
(Invitrogen) and that of freshwater is around 15 mOsm kg−1. All
experiments and exposures are based on individual inserts (n)
derived from at least one biological replicate. Due to the seeding
procedure over two  days, one biological replicate is derived from
two ﬁsh.
2.3. Membrane permeability
Paracellular permeability was measured using the paracellu-
lar marker 14C-mannitol (20 Ci mmol−1, Amersham Biosciences,
CAS no. 88404-24-4). Thirty-seven DSI epithelia with TER val-
ues ranging from 0 to 14 k cm2 were exposed to 0.013 Ci
(2.2 × 105 dpm) 14C-mannitol in 1.5 mL  sterile freshwater in the
apical compartment, with 2.0 mL  L-15 medium in the basal
(Hubatsch et al., 2007). From this, a TER value at which paracellular
transport is at its most minimal can be deduced as a threshold for
when epithelia are ready for transport assays (≥5 k cm2). Aliquots
of 100 L were taken from the apical and basal compartments at
time 0 and 24 h, and placed in 2 mL liquid scintillation ﬂuid (Ecol-
ume) and radioactivity measured by beta counting (Tri Carb 460CD
liquid scintillation system; Packard). Mannitol ﬂux after 24 h was
calculated using Eq. (1):
Permeability (cm s−1) = [M]BL × volume
MAP × time × 3600 × area
(1)
where [M]BL is the change in radioactivity in the basal compart-
ment, MAP is the radioactivity at the start, time is 24 h and area is
0.9 cm2 (Fletcher et al., 2000).
2.4. Radiolabeled pharmaceuticals
All drugs used in transport assays were at a concentration
of 1 g L−1 to represent the levels detected in the environment
whilst remaining within detectable limits (Table 1). These were
purchased radiolabeled and re-suspended in ethanol or methanol
with a ﬁnal solvent concentration in assay conditions of <0.0003%,
and chosen to demonstrate a range of different classes (1-,
2- and non-speciﬁc -receptor agonists, a H2-receptor agonist
and a tricyclic anti-depressant) with mid-range log Kow values
(see Table 1). This method of using labeled compounds allows
for the recovery of label during cell-free conditions to calculate
the amount that sticks to plastic ware. Furthermore, the label
may  be detected as either the parent compound or biotrans-
formed products. 3H-propranolol hydrochloride (29.0 Ci mmol−1,
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Table  1
Properties of selected pharmaceuticals and the levels at which they are found in the environment.
Pharmaceutical Use MW pKa log Kow1 log Kow2 Environmental levels (ng L−1)
Propranolol Non-selective  antagonist 259.340 9.4 2.54 1.12* 333
Metoprolol 1 receptor antagonist 267.364 9.6 1.76 –0.90# 4103
Atenolol 1 receptor antagonist 266.336 9.6 0.67 0.0015* 9403
Formoterol Long-acting 2 agonist 344.405 7.9a/9.2b 1.93 0.41* n/a
Terbutaline 2-Adrenergic receptor agonist 225.284 8.86a/9.76b 1.25 1.29 74
Ranitidine H2-receptor antagonist 314.4 8.08 1.47 1203
Imipramine Tricyclic antidepressant 280.407 9.4 4.39 0.145
1 Parameter Client (Tetko et al., 2005).
2 Environmental Risk Assessment data, experimentally measured values (AstraZeneca, 2014).
3 Kostich et al. (2014).
4 Breitholtz et al. (2012).
5 Giebułtowicz and Nałe˛cz-Jawecki (2014).
a Acidic.
b Basic
* pH 7.4.
# pH 7.
CAS no. 152588-63-93) was obtained from Amersham Biosciences.
3H-metoprolol (29.7 Ci mmol−1), 3H-formoterol (18.5 Ci mmol−1)
and 3H-terbutaline (29.0 Ci mmol−1) were obtained from Vit-
rax. 3H-Atenolol (7.3 Ci mmol−1) and 3H-ranitidine (2.5 Ci mmol−1)
were obtained from Moravek Biochemicals, and 3H-imipramine
hydrochloride (48.5 Ci mmol−1, CAS no. 113-52-0) from Perkin-
Elmer.
2.5. Bidirectional transport assays and apparent permeability
coefﬁcients
Bidirectional transport assays (BTA) assess both passive and
facilitated transport in a bidirectional manner, from apical to basal
(uptake) or vice versa (efﬂux). In these, concentration gradient con-
ditions exist, whereby total transport is a sum of both passive
transcellular and carrier-mediated processes. DSI epithelia with a
TER > 5 k cm2 with low paracellular transport rates were exposed
to test compounds in either symmetrical or asymmetrical condi-
tions. Symmetrical contained 1.5 and 2.0 mL  L-15 (without FBS) in
apical and basal compartments respectively, whilst asymmetrical
required the application of 1.5 mL  freshwater in the apical compart-
ment and 2.0 mL  L-15 in the basal. The test compound was  added to
either the apical side (uptake; A:B) or basal compartment (efﬂux;
B:A) at a concentration of 1 g L−1. Each experimental condition
used 3–5 epithelial inserts from 1 to 2 biological replicates. For all
experiments the water or media from the apical or basal compart-
ment was mixed before taking 100 L samples at 0, 6, 24, 30 and
48 h. Each 100 L aliquot sample was placed into scintillation vials
with scintillation ﬂuid and beta-counted, and the drug concentra-
tion was calculated from the speciﬁc radioactivities. For uptake and
efﬂux BTA, apparent permeability coefﬁcients (Papp) at 6 h were
calculated using Eq. (2):
Papp(cm s−1) = (dQ/dt  × 1/(A × C0))3600 (2)
where dQ/dt is the ﬂux rate of the drug (pmol L−1 h−1), A is the
surface area of the monolayer (0.9 cm2) and C0 is the initial con-
centration of the drug in the donor compartment (fM) (Petri et al.,
2004). Transport ratios (TR) for both uptake and efﬂux were calcu-
lated using Eqs. (3) and (4) (Schwab et al., 2003).
Uptake TR = Papp A:B
Papp B:A
(3)
Efﬂux TR = Papp B:A
PappA:B
(4)
An uptake or efﬂux TR ≥ 1.5 is considered an indicator of active
transport (Schwab et al., 2003; Luna-Tortós et al., 2008). For
time-dependent BTA, the results were also expressed as the per-
centage of the initial drug concentration of the donor compartment
for uptake (A:B) and efﬂux (B:A) over 48 h.
2.6. Concentration equilibrium transport assays
Concentration equilibrium transport assays (CETA) examine
transport by adding equivalent concentrations on either side
of the gill epithelium and assessing the movement of com-
pounds over time to evaluate carrier-mediated uptake or efﬂux
regardless of passive transport processes, as used in blood–brain
barrier transport assays (Luna-Tortós et al., 2008). The same
experimental procedures for BTA were used (in symmetrical and
asymmetrical conditions), but with both apical and basal com-
partments containing test drugs at the same concentration of
1 g L−1. The results are expressed as a percentage of the ini-
tial concentration in each compartment (apical or basal) over
time.
2.7. The pH-dependent transport of propranolol
DSI epithelia were exposed in apical freshwater adjusted to pH
6 (by addition of HCl), pH 8 or pH 9.5 (by addition of NaOH; Corning
pH meter 140). Radiolabeled propranolol was  added at a concentra-
tion of 1 g L−1 to either the apical or basal compartments (BTA) to
investigate uptake and efﬂux. At 6 h a 100 L sample was collected
from the apical and basal compartments and radioactivity analyzed
as above, and apparent permeability coefﬁcients (Papp) calculated
using Eq. (2).
2.8. The concentration-dependent uptake of propranolol
DSI epithelia (n = 54) were exposed to 17 concentrations of
propranolol ranging from 0.014 to 10,000 g L−1. Concentrations
above 0.1 g L−1 were made using propranolol hydrochloride
(Sigma, CAS no. 318-98-9) and radiolabeled propranolol as a
marker. Experiments were conducted in asymmetrical conditions
with propranolol added to the water in the apical compart-
ment, thus mimicking the in vivo scenario (Owen et al., 2009).
Radioactivity was  analyzed as previously described in Section
2.3.
2.9. The inhibition of the uptake of propranolol
Cells were pre-incubated with inhibitor at a concentration
100 times higher (400 nM)  than that of propranolol to competi-
tively inhibit the membrane channel. Amantadine (Sigma, CAS no.
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768-94-5), cimetidine (ICN, CAS no. 51481-61-9), cyclosporine A
(Fluka, CAS no. 59865-13-3), MK571 (Tocris Biosciences, CAS no.
115104-28-4), quinidine (Sigma, CAS no. 56-54-2) or verapamil
hydrochloride (Fluka, CAS no. 152-11-4) were dissolved in DMSO
(0.1% in ﬁnal solution) and added to the apical (in 0.75 mL  freshwa-
ter) or basal (in 1.0 mL  L-15 medium). Controls and compartments
without inhibitor contained 0.1% DMSO. After 1 h, volumes were
replaced with 1.5 mL  freshwater containing 1 g L−1 (4 nM)  pro-
pranolol apically and 2.0 mL  L-15 basally, whilst keeping the ﬁnal
concentration of inhibitor at 400 nM throughout. The same samp-
ling procedure as for BTA at time 0, 6 (not for cyclosporine A), 24,
36 and 48 h proceeded and the uptake Papp of propranolol was  cal-
culated using Eq. (2). The Papp in all inhibitor-free controls were
expressed as a percentage of the mean (100%) and the change in
uptake Papp (inhibition) in the presence of inhibitors was  expressed
as a percentage of this mean control.
2.10. Analysis of data and statistics
For bidirectional Papp comparisons between the uptake and
efﬂux, an independent samples t-test with equal variances assumed
was used and statistical signiﬁcance was accepted when P < 0.05
(SPSS software, SPSS Inc.). The same statistical analysis was used
to test for differences between asymmetrical and symmetrical
uptake or efﬂux Papp for each drug to assess the effect of apical
freshwater application. For the time-dependent BTA signiﬁcant dif-
ferences between the uptake and efﬂux percentage of the donor
compartment were tested for by one-way analysis of variance
(ANOVA) on log-transformed data (SPSS software, SPSS Inc.). For
the time-dependent CETA the statistical signiﬁcance of differences
between each percentage increase or decrease in the apical or
basal compartments were also tested for by one-way ANOVA (after
log transformation). Differences between the uptake of propra-
nolol at different pHs, and similarly the efﬂux, were tested for
by ANOVA and statistical signiﬁcance was accepted when P < 0.05
(SPSS software, SPSS Inc.). The propranolol ﬂux for each concen-
tration in the concentration–response evaluation was  calculated
at 6 h and analyzed by ordinary least squares linear regression
to describe the best ﬁt, and further analysis of low concentra-
tions was done by cubic polynomial regression to best describe
the relationship (SPSS software, SPSS Inc.). Statistical differences
between inhibitor (applied either apically or basally) and the
inhibitor-free control were tested for by one-way ANOVA (after
log transformation) and the statistical signiﬁcance was set to
P < 0.05.
2.11. Comparison to predicted and actual plasma concentrations
In vitro propranolol ‘internal’ concentrations after uptake (A:B)
from the concentration–response study were compared to pre-
dicted in silico and actual in vivo plasma concentrations of
propranolol in Oncorhynchus mykiss.  The predicted partition of
propranolol between blood and water can be determined by
[plasma] = 0.87 [water] as described by Owen et al. (2009). This
was calculated using the mammalian ﬁsh leverage model, whereby
the predicted plasma concentration can be described by multi-
plying the environmental concentration by the blood to water
partitioning coefﬁcient (Huggett et al., 2004) using the Fitzsim-
mons model for the partitioning of compounds between blood and
water (Fitzsimmons et al., 2001). Actual plasma concentrations of
propranolol in O. mykiss were obtained from Owen et al. (2009).
In vitro propranolol concentrations at 6 h (n = 3–6 from 3 biolog-
ical replicates) were tested for correlation to in silico and in vivo
plasma concentrations by ordinary least squares linear regression
(SPSS software, SPSS Inc.)
0
1
2
3
4
0 5 10 15
P
e
rm
e
a
b
il
it
y
 (
1
 x
 1
0
-6
c
m
 s
-1
)
Resistance  (k Ω cm2)
Fig. 1. The relationship between 14C-mannitol permeability (after 24 h) and
transepithelial electrical resistance (TER) in 37 cultured rainbow trout gill epithelia
derived from four biological replicates. 14C-mannitol was applied to the apical com-
partment in freshwater, with L-15 medium in the basal compartment. Each data
point represents one DSI epithelium (n = 37) from four biological replicates.
3. Results
3.1. Epithelium membrane characteristics
DSI epithelial development was  monitored through daily mea-
surements of TER in symmetrical conditions, which after 8 days
reached 18.1 ± 1.3 k cm2 (n = 24). After apical freshwater appli-
cation TEP became increasingly negative from −0.9 ± 0.15 mV
to −12.9 ± 2.9 mV  (n = 8). The permeability of the paracellu-
lar marker 14C-mannitol produces a measure of the rate of
paracellular transport for compounds with similar molecular
weights via this route. Mannitol ﬂux in cell free inserts with
a TER of 0  cm2 (blanked) was  3.6 ± 0.2 × 10−6 cm s−1 (n = 4,
Fig. 1). DSI gill epithelia with TER of 200–1000  cm2 exhib-
ited a mannitol permeability of 1.1 ± 1.1 × 10−6 cm s−1, whilst
those >2 k cm2 showed the lowest mannitol permeability of
0.1 ± 0.01 × 10−6 cm s−1, with little variation between epithelia
(Fig. 1).
3.2. Apparent permeability coefﬁcients and transport ratios
In symmetrical conditions with L-15 medium on both sides of
the gill cell epithelium no signiﬁcant differences between Papp A:B
and Papp B:A for all 7 pharmaceuticals was observed (Fig. 2A), yet
all permeabilities were higher than that of the paracellular marker
mannitol (except for atenolol; Papp A:B: 0.1 ± 0.03 × 10−6 cm s−1
and Papp B:A: 0.1 ± 0.02 × 10−6 cm s−1 compared to mannitol;
Papp A:B: 0.1 ± 0.01 × 10−6 cm s−1). In asymmetrical conditions
with freshwater at the apical surface of the gill epithelium,
Papp A:B was signiﬁcantly higher than Papp B:A (P < 0.001) for
propranolol and imipramine, whilst no signiﬁcant differences
existed between uptake and efﬂux Papp of the remaining ﬁve
drugs metoprolol, atenolol, formoterol, terbutaline and ranitidine
(Fig. 2B). For propranolol, the Papp A:B increased signiﬁcantly from
1.7 ± 0.2 × 10−6 cm s−1 in symmetrical to 2.7 ± 0.2 × 10−6 cm s−1 in
asymmetrical conditions (P < 0.05) and Papp B:A decreased signiﬁ-
cantly from 1.1 ± 0.02 to 0.8 ± 0.1 × 10−6 cm s−1 (P < 0.05) (Fig. 2A
and B). Similarly for imipramine a signiﬁcant increase in Papp
A:B from symmetrical (1.9 ± 0.2 × 10−6 cm s−1) to asymmetrical
(3.0 ± 0.1 × 10−6 cm s−1; P < 0.05) and a signiﬁcant decrease in Papp
L.C. Stott et al. / Aquatic Toxicology 159 (2015) 127–137 131
Table  2
The uptake and efﬂux transport ratios (TR) of seven drugs in symmetrical and asym-
metrical conditions.
Uptake TR Efﬂux TR
Symmetrical Asymmetrical Symmetrical Asymmetrical
Propranolol 1.52* 3.21* 0.66 0.31
Metoprolol 0.56 1.32 1.78* 0.76
Atenolol 0.74 0.60 1.34 1.67*
Formoterol 1.08 0.97 0.93 1.03
Terbutaline 0.92 0.89 1.09 1.13
Ranitidine 1.21 0.88 0.83 1.14
Imipramine 0.84 1.83* 1.19 0.55
* represents TR ≥ 1.5.
B:A (2.2 ± 0.04 to 1.6 ± 0.1 × 10−6 cm s−1; P < 0.05) (Fig. 2A and B)
was observed.
Propranolol showed uptake TR values greater than 1.5
in both symmetrical and asymmetrical conditions, whilst for
imipramine; this was only observed in asymmetrical conditions.
Both metoprolol and atenolol had efﬂux TR values greater than
1.5 in symmetrical and asymmetrical conditions, respectively
(Table 2).
3.3. Bidirectional transport assays
In symmetrical conditions with L-15 medium on both sides
of the epithelium, ranitidine and imipramine exhibited greater
efﬂux transport from the basal to the apical compartments at 24 h
(P < 0.05) and at 30 and 48 h (P < 0.05) respectively. In asymmetri-
cal conditions involving the application of freshwater at the apical
surface, more propranolol, ranitidine and imipramine were taken
up across the gill cell surface than efﬂuxed after 48 h. This was sig-
niﬁcantly more so at 6 h (P < 0.001) and 24, 30 and 48 h (P < 0.01)
for propranolol, 30 h (P < 0.01) for ranitidine and at all sampling
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Fig. 2. The apparent permeability coefﬁcients (Papp) for uptake (Papp A:B, white bars)
and efﬂux (Papp B:A, gray bars) of seven pharmaceuticals (1 g L−1) across the DSI gill
cell epithelium at 6 h in symmetrical conditions (A) and asymmetrical conditions (B).
Signiﬁcant differences between the Papp A:B and Papp B:A for a drug within a condition
(symmetrical or asymmetrical) are indicated by asterisk (independent samples t-
test; ***P < 0.001). Signiﬁcant differences between symmetrical and asymmetrical
Papp A:B or Papp B:A for each drug are indicated by hash tag in (B) (independent samples
t-test; #P < 0.05). All experiments were performed in triplicate or more (n = 3–5) from
at  least one biological replicate and values are shown as means ± SEM.
points (6, 24, 30 and 48 h) for imipramine (P < 0.001). Metopro-
lol, formoterol and terbutaline showed slightly greater uptake than
efﬂux after 48 h, and this was signiﬁcantly more so for formoterol
at 48 h (P < 0.05).
3.4. Concentration-equilibrated transport assays
In symmetrical conditions with L-15 media and test drug on
both sides of the epithelium no signiﬁcant differences between
percentage of the initial drug concentrations in the apical and
basal compartments were observed for metoprolol, terbutaline
and ranitidine at any time point (Fig. 3B). The percentage of the
initial concentration of formoterol was more in the apical than
basal but only signiﬁcantly so at 24 h (P < 0.05). The percentage
of the initial concentration of propranolol in the apical compart-
ment was  signiﬁcantly more than the basal at all sampling points
after 0 h (6 and 24 h P < 0.01 and 30 and 48 h P < 0.05). This was
also seen for imipramine, which showed the same increased basal
to apical facilitated transport (P < 0.001 at 6, 24 and 30 h and
P < 0.01 at 48 h). However, in asymmetrical conditions the situ-
ation was  reversed whereby increased apical to basal transport,
indicative of facilitated uptake, resulted in signiﬁcantly more pro-
pranolol and imipramine in the basal compartments (P < 0.01 at
24 h and P < 0.001 to 30 and 48 h for propranolol and P < 0.01
at 6, 24 and 30 h and P < 0.001 at 48 h for imipramine). The
same was  true for ranitidine in asymmetrical conditions but to
a lesser degree (P < 0.05 at 24, 30 and 48 h). Metoprolol, for-
moterol and terbutaline showed no signs of facilitated transport
across the epithelium as no signiﬁcant differences were observed
(Fig. 3B).
3.5. The pH-dependent transport of propranolol
A decrease in pH from 8 to 6 resulted in a signiﬁcant reduc-
tion in the uptake permeability (Papp A:B) of propranolol from
2.7 ± 0.2 × 10−6 to 0.4 ± 0.03 × 10−6 cm s−1 (P < 0.001) in asymmet-
rical conditions. The effect was  opposite for efﬂux permeability
(Papp B:A) with an increase from 0.8 ± 0.1 to 2.8 ± 0.1 × 10−6 cm s−1
(P < 0.001; Fig. 4). An increase in pH from 8 to 9.5 was without
signiﬁcant effect (Fig. 4).
3.6. The concentration-dependent uptake of propranolol
A positive linear correlation between concentration
(0.014–10,000 g L−1) and ﬂux of propranolol was  observed
with regression line representing the best ﬁt of [rate] = 0.052
[concentration] (n = 54, r2 = 0.974, Fig. 5A). However, at lower
propranolol concentrations (0.014–0.14 g L−1) a 2nd order poly-
nomial regression best described the concentration–response
relationship (n = 24, r2 = 0.927, Fig. 5B) rather than linear (n = 24,
r2 = 0.908) with line representing the best ﬁt of [rate] = 0.057
[concentration].
3.7. The inhibition of the uptake of propranolol
Amantadine and verapamil did not inhibit Papp A:B of propranolol
(Fig. 6A and F). Apical and basal cimetidine application signiﬁcantly
inhibited the transport of propranolol at all time points (apart
from basal at time 6 h) by approximately 40–61.4% ± 3.4 (apical
application) and 55.9% ± 1.3 (basal application) at 48 h (P < 0.001)
(Fig. 6B). Similarly, cyclosporine A showed a signiﬁcant inhibition
of propranolol transport after 48 h to 69.9% (±3.7) of that in the con-
trol (P < 0.01) for apical application andto 66.3% (±6.1) (P < 0.001)
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Fig. 3. The transport assays of six pharmaceuticals: propranolol, metoprolol, formoterol, terbutaline, ranitidine and imipramine, in the DSI rainbow trout primary gill cell
system over 48 h under (A) bidirectional transport assays (BTA) and (B) concentration equilibrium transport assays (CETA) conditions. For BTA (A) the drug is applied at a
concentration of 1 g L−1 to either the apical (–––) for apical to basal transport; uptake, A:B or basal compartment (– – –) for basal to apical transport; efﬂux, B:A in either
symmetrical (L-15 medium in both compartments) or asymmetrical (freshwater in the apical compartment and L-15 medium in the basal) conditions. For this assay, data
are  shown as a percentage of the initial drug concentration in the donor chamber versus time. For CETA (B), the drug is added to both the apical and basal compartments
at  the same concentration (1 g L−1) in both symmetrical and asymmetrical conditions. Data are shown as a percentage of the initial concentration in either the apical or
basal  versus time. For both assays, signiﬁcant differences between the two  compartments are indicated by asterisk (one-way ANOVA; *P < 0.05; **P < 0.01; ***P < 0.001). All
experiments were performed in triplicate or more (n = 3–6) from at least one biological replicate and values are shown as means ± SEM.
for basal one (Fig. 6C). Application of the inhibitors MK571 and
quinidine again caused a signiﬁcant decrease in propranolol per-
meability over time by approximately 40% compared to the control
at 48 h for both apical and basal applications (P < 0.001) (Fig. 6D
and E).
3.8. Comparison to predicted and actual propranolol plasma
concentrations
Predicted plasma concentrations were calculated using
[plasma] = 0.87 [water] and actual plasma concentrations from
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Table  3
Propranolol concentration in silico (predicted), in vivo and in vitro (measured at various external propranolol concentrations).
Nominal propranolol concentration in water (g L−1) In silico (ng mL−1) (Huggett et al., 2004) In vivo (ng mL−1) (Owen et al., 2009) In vitro (ng mL−1)
0.1 0.087 n/a 0.04 (±0.002)
1.0 0.87 0.94* (n/a) 0.10 (±0.001)
10  8.7 3.3 (±0.4) 0.72 (±0.02)
100  87 16 (±7) 7.5 (±0.3)
1000 870 280 (±116) 79.5 (±7.3)
10,000 8700 5200 (±1333) 812 (±158)
100,000 87,000 n/a 5545 (±313)
* Pooled plasma sample.
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Fig. 4. The pH-dependent uptake of propranolol. Shown are the apparent perme-
ability coefﬁcients (Papp) for uptake (Papp A:B, white bars) and efﬂux (Papp B:A, gray
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were performed in triplicate or more (n = 3–5) from two  biological replicates and
values are shown as means ± SEM.
Owen et al. (2009) (Table 3). A linear correlation between pre-
dicted plasma concentration and in vitro basal concentrations was
obtained and described by [in vitro] = 0.063 [predicted] (n = 21,
r2 = 0.995, Fig. 7). Furthermore, a correlation between actual
plasma concentrations (Owen et al., 2009) and in vitro basal
concentrations was obtained and described by [in vitro] = 0.155
[actual] (n = 21, r2 = 0.966, Fig. 7).
4. Discussion
The development of suitable in vitro cellular models to replace,
reﬁne and reduce (3Rs) the numbers of ﬁsh used in ecotoxicological
studies is an important requirement in current regulatory testing
(Scholz et al., 2013). Pharmaceuticals in the environment are con-
taminants of emerging concern and their behavior in water affects
uptake into biological systems (Boxall et al., 2012). Log Kow is often
used to determine the bioconcentration potential of a compound
which may  not be relevant to ionizable compounds such as pharma-
ceuticals (Hermens et al., 2013). The pH-corrected log Dow is used
to account for the fraction of ionizable and nonionisable species of a
substance at a given pH, but this accounts for partitioning between
two liquid phases and does not include partitioning across a biolog-
ical membrane. The present study is the ﬁrst to demonstrate how a
primary rainbow trout gill cell culture system can be used to assess
pharmaceutical uptake from water across a biological membrane.
Therefore, this offers a potential alternative to replace whole organ-
ism pharmaceutical uptake studies at differing water chemistries,
such as different pHs, the presence of dissolved organic matter or
real water samples from the ﬁeld.
Once a tight epithelium (>5 k cm2) has formed, the gills
present a barrier for paracellular transport that is relatively imper-
meable to the paracellular permeability marker 14C-mannitol
(Fig. 1). All pharmaceuticals (except atenolol) were transported
across the epithelium in both directions at a rate greater than that of
14C-mannitol, indicating that their transport is via a transcellular or
carrier-mediated process, as all exhibit molecular weights greater
than that of the marker (Hubatsch et al., 2007; Schwab et al., 2003).
The application of apical freshwater resulted in signiﬁcantly dif-
ferent drug permeations for propranolol and imipramine where
more is taken up across the epithelium from the water than efﬂuxed
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Fig. 6. The inhibition of the uptake of 1 g L−1 (4 nM)  propranolol from apical (freshwater) to basal (L-15 medium) using 400 nM of the six inhibitors amantadine (A); cimetidine
(B);  cyclosporine A (C); MK571 (D); quinidine (E) and verapamil (F), applied either apically, AP (–––) or basally, BL (– – –). Data are shown as percentage of the mean control, CTL
(·  · ·· · ·) over time. Signiﬁcant differences between the apically applied inhibitor and the control are indicated by asterisk (one-way ANOVA; *P < 0.05; **P < 0.01; ***P < 0.001).
Signiﬁcant differences between the basally applied inhibitor and the control are indicated by hash tag (#P < 0.05; ##P < 0.01; ###P < 0.001). All experiments were performed in
triplicate or more (n = 3–6 from at least one biological replicate for inhibitor studies; n = 18 from six biological replicates for the inhibitor free controls) and values are shown
as  means ± SEM.
from the basolateral compartment (Table 2; Figs. 2B and 3A). The
uptake of ionizable chemicals such as pharmaceuticals depends on
pH and the acid base constant (pKa) (Lahti et al., 2011). Both pro-
pranolol and imipramine are weak bases with pKa values around
9.5. Using the Henderson–Hasselbalch equation, 99% of propranolol
and imipramine exist in their protonated ionized form at pH 7.4 in
symmetrical conditions, which then falls to only 98% in freshwa-
ter at pH 8. Here, at pH 8, more of the natural unionized forms
are lipid-soluble, and thus may  cross the membrane via passive
transcellular routes explaining the enhanced uptake. However, the
1% change in speciation is unlikely to fully account for the differ-
ence in uptake observed (Fig. 2) and other factors are likely to
play a role. For example, in symmetrical conditions TEP is posi-
tive (1.9 ± 0.2 mV)  and becomes negative after apical freshwater
application (−10.3 ± 0.2 mV,  Fletcher et al., 2000; −12.9 ± 2.9 mV,
data not shown), to a value similar to that observed in vivo (Potts,
1984). The change in membrane potential to basolateral negative
generates an electrical gradient that aids cation partitioning across
the membrane (Fletcher et al., 2000). Alternatively, the TR values
greater than 1.5 in asymmetrical conditions for propranolol and
imipramine in BTA conditions (Table 2) indicate that a proportion
of the transport is via an carrier-mediated process (Schwab et al.,
2003). This observation was substantiated by the concentration
equilibrium transport assay (CETA) that eliminates concentration-
dependent passive transport across the gill epithelium allowing
the observation of carrier-mediated processes that drive xenobio-
tic transport. In CETA the difference in partitioning of radioactivity
between the two compartments is not due to disproportional loss of
compound adhering to the plastic ware of the apical and basolateral
compartments, since in cell free blank insert experiments an equal
percentage of the initial concentration added was absorbed to each
compartment and an 80% recovery was obtained after 48 h (data
not shown). Thus, it is possible to conclude that for propranolol
and imipramine, facilitated transport makes up approximately 10%
of the total transport, and around 5% for ranitidine efﬂux (Fig. 3B).
Uptake rates are important for predicting potential internal con-
centrations and are used to predict effects based on the “read
across” hypothesis and Mode of Action (Rand-Weaver et al., 2013).
Much of the in vivo uptake work used for these predictions expose
ﬁsh to very high water concentrations and extrapolates back to
these lower environmentally relevant values. Propranolol uptake
is concentration-dependent over the whole range of concentra-
tions but in the low, ng L−1 range, uptake deviates from linearity
(0.014–0.14 g L−1, Fig. 5). A similar result was obtained for the
uptake at very low concentrations of iron across zebraﬁsh gills and
was attributable to proton-dependent metal transporters (Bury and
Grosell, 2003). The facilitated transport of propranolol that occurs
in these environmentally relevant concentrations (Kostich et al.,
2014) is of interest because it suggests that the predictive mod-
els for uptake using data derived for higher concentrations may
underestimate uptake.
The uptake of propranolol is pH dependent up to pH 8, after
which further increases do not cause signiﬁcant effects (Fig. 4). This
again could be attributed to the difference in composition of ion-
ized and unionized species at different pHs, with a caveat that a
proportion of transport is likely via a facilitated process. However, it
should be noted that the pH of the apical bulk compartment, and the
microclimate at the boundary layer, were not measured after the
6 h duration of the experiment, and variations in such may  account
for changes in drug uptake. pH-dependent uptake of propranolol
has been observed in other epithelia including retina (Kubo et al.,
2013), Caco-2 cells (Wang et al., 2010) and kidney MDCK cells
(Dudley et al., 2000). In contrast, efﬂux of propranolol is far greater
at pH 6 than uptake (Fig. 4). This may  suggest the export of pro-
pranolol or its metabolite is pH-dependent. Candidates for drug
export are the ABC transporters; however these are not directly
regulated by pH changes (Altenberg et al., 1993; Neuhoff et al.,
2003). The internal pH of the cells is constant against external pH
changes and thus intracellular speciation of the drug is unlikely to
explain potential increase in efﬂux. It is likely that there are other
propranolol parent and/or metabolite exporters present on the
gill.
Propranolol uptake from water was inhibited by cimetidine,
cyclosporine A, MK571 and quinidine. These are inhibitors of a
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Fig. 7. Propranolol concentrations in the basal compartment of the primary gill cell model after 6 h apical exposure to propranolol in asymmetrical conditions plotted against
(A)  predicted (see text) Oncorhynchus mykiss propranolol plasma concentrations (0.1–100,000 g L−1) with regression line representing the ﬁt of [in vitro] = 0.063 [predicted]
(n  = 21, r2 = 0.995) or (B) actual in vivo plasma concentrations (1–10,000 g L−1) after 40 days exposure (Owen et al., 2009) with the regression line representing the ﬁt of [in
vitro]  = 0.155 [actual] (n = 21, r2 = 0.966) (Table 3). Basal in vitro concentrations were performed in triplicate or more (n = 3–5) and represent mean ± SEM from three biological
replicates.
number solute carrier and ABC transporters. A number of human
SLCs implicated in drug transport (SLC15s, SLCOs, SLC22s and
SLC47s [Dobson and Kell, 2008; Giacomini et al., 2010]) are homol-
ogous to SLCs found in teleost ﬁsh (Verri et al., 2012). Similarly,
ATP-binding cassette (ABC) transporters involved in the cellular
efﬂux of toxicants such as ABCBs, ABCCs and ABCG2 (Deeley et al.,
2006) are considered highly conserved amongst vertebrates (Dean
and Annilo, 2005) and have been documented in rainbow trout
cells both in vivo and in vitro (Fischer et al., 2011; Loncˇar et al.,
2010) but not fully characterized. Recent microarray studies using
the primary gill cell culture system have indentiﬁed the presence
of transcripts for genes encoding a number of SLCs, ABCs as well
as biotransformation enzymes (Schnell, Bury, Kille and Hogstrand,
unpublished data). But, the identiﬁcation of active proteins requires
further work.
The application of cimetidine and quinidine, which both interact
with organic cation transporter OCT2 (SLC22A2) (Giacomini et al.,
2010; Koepsell, 2013) signiﬁcantly reduce propranolol uptake. Pro-
pranolol transport via OCT2 was observed in renal LLC-PK1 cells
transiently transfected with hOCT2-V5, more speciﬁcally in the
active uptake of its cationic form across the apical membrane
(Dudley et al., 2000). Cimetidine is also used as a blocker of cisplatin
transport by OCT2 in zebraﬁsh lateral line hair cells (Thomas et al.,
2013) and the presence of OCT2-like proteins have been suggested
in other teleost ﬁsh gill epithelia (Verri et al., 2012). MK571 is an
inhibitor of the multidrug resistance protein (MRP) efﬂux pumps
(Deeley et al., 2006) and signiﬁcantly inhibited propranolol uptake.
The main MRP  expressed in the gill is MRP3 (ABCC3) (Loncˇar et al.,
2010). P-glycoprotein (Pgp; ABCB1) is implicated in propranolol
transport in rabbit conjunctivial epithelial cells (Yang et al., 2000)
and Caco-2 cells (Wang et al., 2010) and is present in rainbow trout
tissues but at low levels in the gill (Loncˇar et al., 2010). Whether
Pgp is involved in propranolol transport in the gill cell culture sys-
tem is unclear. In addition to inhibiting OCT2, quinidine also acts as
Pgp inhibitor (Giacomini et al., 2010) and cyclosporine A, another
Pgp inhibitor, also blocked propranolol transport but this may  be
via MRP  inhibition instead. Application of the Pgp inhibitor vera-
pamil, however, did not affect propranolol transport (Fig. 6F). Taken
together these observations would suggest that OCT2 and MRP3
may  be candidates for propranolol transport across the teleost gill
epithelium, but the location (apical or basolateral membrane) of
these transporters, and others, needs further assessment.
Owen et al. (2009) showed that predicted plasma concentra-
tions (Fitzsimmons et al., 2001) were good indicators of propranolol
uptake over a range of high concentrations. Our data also correlates
well with predicted (Fig. 7A) and measured plasma concentrations
(Fig. 7B). However, in vitro propranolol concentrations in the baso-
lateral compartment were an average 6% of the predicted and 16% of
actual plasma concentrations, whilst actual plasma concentrations
were only 59% of predicted (Owen et al., 2009). In vivo bioconcen-
tration studies can involve an uptake phase of 60 days until a steady
state is reached (OECD305; OECD, 2012). Owen et al. (2009) used a
40-day exposure period, and both procedures use a ﬂow through
system with a steady-state endpoint. Our in vitro assay took place
over 6 h in a static system, which could account for reduced propra-
nolol uptake. Furthermore, actual plasma concentrations may  be
lower than predicted as a proportion of the drug may  bind to pro-
teins or be metabolized by the gill (as suggested by Bartram et al.,
2011), which prediction models fail to take into account. Neverthe-
less, the relationships between this in vitro system to predicted and
actual propranolol plasma concentrations suggest its applicability
as a suitable in vitro model to investigate the uptake of xenobi-
otics and when combined with elimination rates, may supplement
in vivo bioconcentration ﬁsh studies. These model pharmaceuticals
used do not bioaccumulate; however, they may  be taken into a
ﬁsh, and or excreted. This functional primary gill model facilitates
our better understanding of these processes. Currently legislation
requires assessment for compounds of log Kow higher than 3. This
is an arbitrary value and we suspect that this value may  be con-
servative with little prospect of signiﬁcant bioaccumulation for
compounds lower than log Kow 4. This model provides a rapid
and ethically acceptable tool with which to perform a preliminary
assessment of compounds of low log Kow, and as such ideal for large
numbers of pharmaceuticals that typically have a lower propensity
to bioaccumulate.
The study shows that as well as the passive uptake and efﬂux
of neutral forms of pharmaceuticals, water enhances drug uptake
of ionizable pharmaceuticals via both passive transcellular and car-
rier mediated processes. Hence, the ability of this system to tolerate
freshwater is fundamental if we are to simulate in vivo drug uptake
across the gill. In addition, the facilitated uptake of propranolol
was more evident at low concentrations that are more environ-
mentally relevant; suggesting that in certain situations uptake may
be under predicted. Indeed there is signiﬁcant variation (ﬁve-fold)
recorded in plasma concentrations of individual ﬁsh exposed to
pharmaceuticals in vivo (Owen et al., 2009), and it could be that
individual difference in transporter expression may be a mechanis-
tic explanation for this variance. The use of this system provides an
opportunity to reduce the numbers of ﬁsh used in regulatory eco-
toxicological testing as the primary gill cells cultured from two  ﬁsh
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may  provide up to 72 individual gill cell cultures, and this method
bypasses in vivo drug exposures and uses much less test compound,
thus offering reﬁnement through improved animal welfare meth-
ods.
Conﬂict of interest statement
The authors declare no ﬁnancial conﬂict of interest.
Acknowledgements
This work was funded via a studentship from Biotechnology and
Biological Sciences Research Council (BBSRC) co funded Case Award
(BB/J500483/1) supported by the AstraZeneca Global Environment
research program to NRB and CH supporting LCS. SS was  supported
by a grant from NC3Rs number 26675 awarded to CH and NRB. SFO
is an employee of AstraZeneca. AstraZeneca is a biopharmaceutical
company specializing in the discovery, development, manufactur-
ing and marketing of prescription medicines, including some of
those used in this study. Funding bodies played no role in the design
of the study or decision to publish. The work aims to identify effec-
tive alternatives to reduce, reﬁne and replace the use of live animals
to meet environmental regulatory tests.
References
Altenberg, G.A., Young, G., Horton, J.K., Glass, D., Belli, J.A., Reuss, L., 1993. Changes in
intra- or extra-cellular pH do not mediate P-glycoprotein-dependent multidrug
resistance. Proc Natl. Acad. Sci. USA 90, 9735–9738.
AstraZeneca, 2014. Environmental risk assessment data. http://www.astrazeneca.
com/Responsibility/The-environment/Pharmaceuticals-in-the-environment/
era-data-2012
Baron, M.G., Purcell, W.M.,  Jackson, S.K., Owen, S.F., Jha, A.N., 2012. Towards a
more representative in vitro method for ﬁsh ecotoxicology: morphological and
biochemical characterisation of three-dimensional spheroidal hepatocytes. Eco-
toxicology 21 (8), 2419–2429.
Bartram, A.E., Winter, M.J., Huggett, D.B., McCormack, P., Constantine, L.A., Het-
heridge, M.J., Hutchinson, T.H., Kinter, L.B., Ericson, J.F., Sumpter, J., Owen,
P.S.F., 2011. In vivo and in vitro liver and gill EROD activity in rainbow trout
(Oncorhynchus mykiss)  exposed to the beta-blocker propranolol. Environ. Toxi-
col. 27 (10), 573–582.
Boxall, A.B., Rudd, M.,  Brooks, B.W., Caldwell, D., Choi, K., Hickmann, S., Innes, E.,
Ostapyk, K., Staveley, J.P., Verslycke, T., 2012. Pharmaceuticals and personal
care products in the environment: what are the big questions? Environ. Health.
Perspect. 120, 1221–1229.
Breitholtz, M., Näslund, M.,  Stråe, D., Borg, H., Grabic, R., Fick, J., 2012. An evaluation
of  free water surface wetlands as tertiary sewage water treatment of micro-
pollutants. Ecotoxicol. Environ. Safe 78, 63–71.
Bury, N.R., Grosell, M.,  2003. Waterborne iron acquisition by a freshwater teleost
ﬁsh, zebraﬁsh Danio rerio. J. Exp. Biol. 206 (19), 3529–3535.
Bury, N.R., Schnell, S., Hogstrand, C., 2014. Gill cell culture systems as models for
aquatic environmental monitoring. J. Exp. Biol. 217, 639–650.
Creton, S., Weltje, L., Hobson, H., Wheeler, J.R., 2013. Reducing the number of ﬁsh in
bioconcentration studies for plant protection products by reducing the number
of  test concentrations. Chemosphere 90 (3), 1300–1304.
Dean, M.,  Annilo, T., 2005. Evolution of the ATP-binding cassette (ABC) transporter
superfamily in vertebrates. Annu. Rev. Genom. Human Genet. 6, 123–142.
Deeley, R.G., Westlake, C., Cole, S.P.C., 2006. Transmembrane transport of endo- and
xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.
Physiol. Rev. 86, 849–899.
Dobson, P.D., Kell, D.B., 2008. Carrier-mediated cellular uptake of pharmaceutical
drugs: an exception or the rule? Nat. Rev. Drug Discov. 7 (3), 205–220.
Dudley, A.J., Bleasby, K., Brown, C.D., 2000. The organic cation transporter OCT2
mediates the uptake of beta-adrenoceptor antagonists across the apical mem-
brane of renal LLC-PK1 cell monolayers. Br. J. Pharmacol. 131 (1), 71–79.
Fischer, S., Loncˇar, J., Zaja, R., Schnell, S., Schirmer, K., Smital, T., Luckenbach, T.,
2011. Constitutive mRNA expression and protein activity levels of nine ABC
efﬂux transporters in seven permanent cell lines derived from different tissues
of  Rainbow Trout (Oncorhynchus mykiss). Aquat. Toxicol. 101, 438–446.
Fitzsimmons, P.N., Fernandez, J.D., Hoffman, A.D., Butterworth, B.C., Nichols, J.W.,
2001. Branchial elimination of superhydrophobic organic compounds by rain-
bow trout (Oncorhynchus mykiss). Aquat. Toxicol. 55, 23–34.
Fletcher, M., Kelly, S.P., Pärt, P., O’Donnell, M.J., Wood, C.M., 2000. Transport prop-
erties of cultured branchial epithelia from freshwater rainbow trout: a novel
preparation with mitochondria-rich cells. J. Exp. Biol. 203, 1523–1537.
Giacomini, K.M., Huang, S., Tweedie, D.J., Benet, L.Z., Brouwer, K.L.R., Chu, X., Dahlin,
A.,  Evers, R., Fischer, V., Hillgren, K.M., et al., 2010. Membrane transporters in
drug development. Nat. Rev. Drug Discov. 9 (3), 215–236.
Giebułtowicz, J., Nałe˛cz-Jawecki, G., 2014. Occurrence of antidepressant residues
in  the sewage-impacted Vistula and Utrata rivers and in tap water in Warsaw
(Poland). Ecotoxicol. Environ. Safe 104, 103–109.
Hansch, C., 1969. A quantitative approach to biochemical structure–activity rela-
tionships. Acc. Chem. Res. 2, 232–239.
Hermens, J.L.M., de Bruijn, J.H.M., Brooke, D.N., 2013. The octanol–water par-
tition coefﬁcient: strengths and limitations. Environ. Toxicol. Chem. 32 (4),
732–733.
Hubatsch, I., Ragnarsson, E.G.E., Artursson, P., 2007. Determination of drug perme-
ability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2
(9), 2111–2119.
Huggett, D.B., Ericson, J.F., Cook, J.C., Williams, R.T., 2004. Plasma concentrations of
human pharmaceuticals as predictors of pharmacological responses in ﬁsh. In:
Kümmerer, K. (Ed.), Pharmaceuticals in the Environment. , 2nd ed. Springer-
Verlag, Berlin, pp. 373–386.
Kostich, M.S., Batt, A.L., Lazorchak, J.M., 2014. Concentrations of prioritized pharma-
ceuticals in efﬂuent from 50 large wastewater treatment plants in the US and
implications for risk estimation. Environ. Pollut. 184, 354–359.
Koepsell, H., 2013. The SLC22 family with transporters of organic cations, anions and
zwitterions. Mol. Aspects Med. 34 (2–3), 413–435.
Kubo, Y., Shimizu, Y., Kusagawa, Y., Akanuma, S.-I., Hosoya, K.-I., 2013. Propranolol
transport across the inner blood–retina barrier: potential involvement of a novel
organic cation transporter. J. Pharmacol. Sci. 102 (9), 3332–3342.
Lahti, M.,  Brozinski, J.-M., Jylhä, A., Kronberg, L., Oikari, A., 2011. Uptake from water,
biotransformation, and biliary excretion of pharmaceuticals by rainbow trout.
Environ. Toxicol. Chem. 30 (6), 1403–1411.
Loncˇar, J., Popovic´, M.,  Zaja, R., Smital, T., 2010. Gene expression analysis of the
ABC  efﬂux transporters in rainbow trout (Oncorhynchus mykiss). Comp. Biochem.
Physiol. 151C (2), 209–215.
Luna-Tortós, C., Fedrowitz, M.,  Löscher, W.,  2008. Several major antiepileptic
drugs are substrates for human P-glycoprotein. Neuropharmacology 55 (8),
1364–1375.
Mckim, J.M., Erickson, R.J., 1991. Environmental impacts on the physiological mech-
anisms controlling xenobiotic transfer across ﬁsh gills. Physiol. Zool. 64 (1),
39–67.
Neuhoff, S., Ungell, A.L., Zamora, I., Artursson, P., 2003. pH-dependent bidirectional
transport of weakly basic drugs across Caco-2 monolayers: implications for
drug–drug interactions. Pharmaceut. Res. 20, 1141–1148.
Owen, S.F., Huggett, D.B., Hutchinson, T.H., Hetheridge, M.J., Kinter, L.B., Ericson,
J.F., Sumpter, J.P., 2009. Uptake of propranolol, a cardiovascular pharmaceutical,
from water into ﬁsh plasma and its effects on growth and organ biometry. Aquat.
Toxicol. 93 (4), 217–224.
OECD, 2012. Test No 305. Bioaccumulation in Fish: Aqueous and Dietary Exposure.
OECD Guidelines for the Testing of Chemicals, Section 3. OECD Publishing.
Petri, N., Tannergren, C., Rungstad, D., Lennernäs, H., 2004. Transport charac-
teristics of fexofenadine in the Caco-2 cell model. Pharmaceut. Res. 21 (8),
1398–1404.
Potts, W.T.W., 1984. Transepithelial potentials in ﬁsh gills. In: Hoar, W.S., Randall,
D.J.  (Eds.), Fish Physiology. Gills, part B Ion and Water Transfer, vol. 6. Academic
Press, Orlando, pp. 105–128.
Rand-Weaver, M.,  Margiotta-Casaluci, L., Patel, A., Panter, G.H., Owen, S.F., Sumpter,
J.P., 2013. The read-across hypothesis and environmental risk assessment of
pharmaceuticals. Environ. Sci. Technol. 47 (20), 11384–11395.
REACH, 2009. Regulation (EC) No 1907/2006 of the European Parliament and of
the  Council of 18 December 2006. Legislation concerning the registration,
evaluation, authorisation and restriction of chemicals. http://eurlex.europa.eu/
LexUriServ/LexUriServ.do?uri=OJ:L:2009:309:0001:0050:EN:PDF
Scholz, S., Sela, E., Blaha, L., Braunbeck, T., Galay-Burgos, M.,  García-Franco, M.,
Guinea, J., Klüver, N., Schirmer, K., Tanneberger, K., et al., 2013. A European
perspective on alternatives to animal testing for environmental hazard iden-
tiﬁcation and risk assessment. Regul. Toxicol. Pharmacol. 67, 506–530.
Schwab, D., Fischer, H., Tabatabaei, A., Poli, S., Huwyler, J., 2003. Comparison of
in  vitro P-glycoprotein screening assays: recommendations for their use in drug
discovery. J. Med. Chem. 46 (9), 1716–1725.
Sugano, K., Kansy, M.,  Artursson, P., Avdeef, A., Bendels, S., Di, L., Ecker, G.F., Faller, B.,
Fischer, H., Gerebtzoff, G., Lennernaes, H., Senner, F., 2010. Coexistence of passive
and  carrier-mediated processes in drug transport. Nat. Rev. Drug Discov. 9 (8),
597–614.
Tetko, I.V., Gasteiger, J., Todeschini, R., Mauri, A., Livingstone, D., Ertl, P., Palyulin,
V.A., Radchenko, E.V., Zeﬁrov, N.S., Makarenko, A.S., Tanchuk, V.Y., Prokopenko,
V.V., 2005. Virtual computational chemistry laboratory – design and description.
J.  Comput. Aid. Mol. Des. 19, 453–463.
Thomas, A.J., Hailey, D.W., Stawicki, T.M., Wu,  P., Cofﬁn, A.B., Rubel, E.W., Raible,
D.W., Simon, J.A., Ou, H.C., 2013. Functional mechanotransduction is required
for  cisplatin-induced hair cell death in the zebraﬁsh lateral line. J. Neurosci. 33
(10), 4405–4414.
Uchea, C., Sarda, S., Schulz-Utermoehl, T., Owen, S., Chipman, K.J., 2013. In vitro mod-
els  of xenobiotic metabolism in trout for use in environmental bioaccumulation
studies. Xenobiotica 43 (5), 421–431.
Verri, T., Terova, G., Romano, A., Barca, A., Pisani, P., Storelli, C., Saroglia, M.,
2012. The solute carrier (SLC) family series in teleost ﬁsh. In: Saroglia, M.,
Liu,  Z. (Eds.), Functional Genomics in Aquaculture. John Wiley and Sons, Inc.,
pp.  219–320.
L.C. Stott et al. / Aquatic Toxicology 159 (2015) 127–137 137
Walker, P.A., Kille, P., Hurley, A., Bury, N.R., Hogstrand, C., 2008. An in vitro method
to  assess toxicity of waterborne metals to ﬁsh. Toxicol. Appl. Pharmacol. 230 (1),
67–77.
Wang, Y.I., Cao, J., Wang, X., Zeng, S.U., 2010. Stereoselective transport and uptake
of propranolol across human intestinal Caco-2 cell monolayers. Chirality 22,
361–368.
Wolf, W.,  De Comber, M.,  Douben, P., Gimeno, S., Holt, M.,  Léonard, M.,  Lillicrap, A.,
Sijm, D., van Egmond, R., Weisbrod, A., Whale, G., 2007. Animal use replacement,
reduction, and reﬁnement: development of an integrated testing strategy for
bioconcentration of chemicals in ﬁsh. Integr. Environ. Assess. Manag. 3 (1), 3–17.
Wood, C.M., Kelly, S.P., Zhou, B., Fletcher, M.,  O’Donnell, M.,  Eletti, B., Pärt, P., 2002.
Cultured gill epithelia as models for the freshwater ﬁsh gill. Biochim. Biophys.
Acta 1566, 72–83.
Yang, J.J., Kim, K.J., Lee, V.H., 2000. Role of P-glycoprotein in restricting propranolol
transport in cultured rabbit conjunctival epithelial cell layers. Pharmaceut. Res.
17  (5), 533–538.
